JP2005200419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005200419A5 JP2005200419A5 JP2005009439A JP2005009439A JP2005200419A5 JP 2005200419 A5 JP2005200419 A5 JP 2005200419A5 JP 2005009439 A JP2005009439 A JP 2005009439A JP 2005009439 A JP2005009439 A JP 2005009439A JP 2005200419 A5 JP2005200419 A5 JP 2005200419A5
- Authority
- JP
- Japan
- Prior art keywords
- agonist
- peroxisome proliferator
- composition
- responsive receptor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53723504P | 2004-01-16 | 2004-01-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005200419A JP2005200419A (ja) | 2005-07-28 |
| JP2005200419A5 true JP2005200419A5 (https=) | 2008-02-28 |
Family
ID=34619679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005009439A Pending JP2005200419A (ja) | 2004-01-16 | 2005-01-17 | 癌治療法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20050209292A1 (https=) |
| EP (1) | EP1555021A1 (https=) |
| JP (1) | JP2005200419A (https=) |
| TW (1) | TWI297606B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2399179T3 (es) * | 2008-08-07 | 2013-03-26 | Pulmagen Therapeutics (Inflammation) Limited | Tratamiento de enfermedad respiratoria |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| US9150534B2 (en) | 2012-02-28 | 2015-10-06 | Northwestern University | Prodrugs of fluorinated mevalonates to inhibit the mevalonate pathway of Streptococcus pneumoniae |
| CA2868311C (en) * | 2012-03-26 | 2021-06-22 | Nippon Chemiphar Co., Ltd. | Use of non-steroidal anti-inflammatory drugs (nsaids) and thiazolidinediones in the treatment of giant cell tumors occurring in a bone or soft tissue or of chondrosarcoma |
| EP2905029B1 (en) | 2012-10-04 | 2018-11-21 | Shionogi&Co., Ltd. | Drug for inhibiting malignant tumor metastasis |
| CN105142631A (zh) * | 2013-01-14 | 2015-12-09 | 健康诊所有限公司 | 抗癌药物和用途 |
| EP3050573B1 (en) | 2013-09-25 | 2019-12-11 | Nippon Chemiphar Co., Ltd. | Zaltoprofen for preventing metastasis of giant cell tumor that occurs in bone or soft parts, metastasis of chondrosarcoma, or metastasis of osteosarcoma |
| CA3060509A1 (en) | 2017-04-21 | 2018-10-25 | Federica Sotgia | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| US11197872B2 (en) | 2017-04-21 | 2021-12-14 | Lunella Biotech, Inc. | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) |
| US12006553B2 (en) | 2017-05-19 | 2024-06-11 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| KR20200010343A (ko) | 2017-05-19 | 2020-01-30 | 루넬라 바이오테크 인코포레이티드 | 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제 |
| US20240058335A1 (en) * | 2021-01-08 | 2024-02-22 | Duke University | Methods for treatment of cancer using abl inhibitors and drugs targeting the mevalonate pathway |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605930A (en) * | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US5798375A (en) * | 1995-07-03 | 1998-08-25 | Sankyo Company, Limited | Treatment of arteriosclerosis and xanthoma |
| JP3651816B2 (ja) * | 1995-07-03 | 2005-05-25 | 三共株式会社 | 動脈硬化症予防および治療剤 |
| EP1410799B1 (en) * | 1996-12-11 | 2010-03-31 | Dana-Farber Cancer Institute, Inc. | Methods and pharmaceutical compositions for inhibiting tumour cell growth |
| UA57081C2 (uk) * | 1997-06-16 | 2003-06-16 | Пфайзер Продактс Інк. | Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування |
| MXPA01009893A (es) * | 1999-04-01 | 2003-07-28 | Esperion Therapeutics Inc | Compuestos con eter, composiciones y usos de estos. |
| WO2001058491A1 (en) * | 2000-02-10 | 2001-08-16 | Takeda Chemical Industries, Ltd. | Drug comprising combination |
| WO2002008188A1 (en) * | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| JP2002128700A (ja) * | 2000-08-16 | 2002-05-09 | Sankyo Co Ltd | 癌を予防及び治療するための医薬組成物 |
| WO2003053974A1 (en) * | 2001-12-21 | 2003-07-03 | Dr. Reddy's Laboratories Ltd. | Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
-
2005
- 2005-01-17 TW TW094101363A patent/TWI297606B/zh not_active IP Right Cessation
- 2005-01-17 JP JP2005009439A patent/JP2005200419A/ja active Pending
- 2005-01-17 EP EP05290099A patent/EP1555021A1/en not_active Ceased
- 2005-01-18 US US11/037,538 patent/US20050209292A1/en not_active Abandoned
-
2008
- 2008-10-14 US US12/250,923 patent/US20090082406A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005200419A5 (https=) | ||
| WO2006084474A3 (en) | A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor | |
| RU2007126483A (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| EA200501586A1 (ru) | Фармацевтические продукты | |
| NO20045434L (no) | En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom | |
| IL163931A (en) | Derivatives of Tetrazycline Compounds Converted by Amino Methyl and Pharmaceutical Preparation Containing Them | |
| JP2006526644A5 (https=) | ||
| NO20033343L (no) | Farmasöytiske doseringsformer av epothiloner for oral administrasjon | |
| MX2007007843A (es) | Formulacion de complejo de inhibidor de 3-hidroxi-3-metil glutaril coa reductasa y agente antihipertensivo, y proceso para su preparacion. | |
| EE04990B1 (et) | HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod | |
| WO2005034908A3 (en) | A solid dosage form comprising a fibrate and a statin | |
| EP2079462A4 (en) | PHARMACEUTICAL COMPOSITIONS OF HDAC INHIBITORS AND CHELABLE METAL COMPOUNDS AND METALO HDAC HEMMER CHELATE COMPLEXES | |
| BRPI0412557A (pt) | forma de dosagem farmacêutica de eventos cardiovasculares | |
| DE602004020649D1 (de) | Hdl-verstärkende kombinationstherapie-komplexe | |
| BRPI0410727A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| EP1619180A4 (en) | CASR ANTAGONIST | |
| NO20074109L (no) | Intravenose formuleringer av PDE-5 inhibitorer | |
| MA31706B1 (fr) | Formulations galéniques de composés organiques | |
| WO2008013833A3 (en) | Orally dissolvable/disintegrable lyophilized dosage forms containing protected particles | |
| RU2010109452A (ru) | Способы и композиции, предназначенные для лечения раковых заболеваний | |
| EA201401042A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ | |
| JP2006512361A5 (https=) | ||
| BRPI0411623A (pt) | forma de dosagem farmacêutica ou dietética, esporopolenina, método para a formação de uma esporopolenina funcionalizada com amina primária ou um outro revestimento de exina, método para a formação de uma esporopolenina funcionalizada com poliamino ou um outro revestimento de exina de um esporo, método para a obtenção de uma esporopolenina funcionalizada com aminoácido ou um outro revestimento de exina de um esporo, esporopolenina funcionalizada ou um outro revestimento de exina de um esporo, forma de dosagem dietética ou flavorizante, método de preenchimento de revestimentos de exina de esporos, uso da forma de dosagem e método de aplicação oral de um ingrediente ativo | |
| EA200801619A1 (ru) | Способ улучшения фармакокинетики ингибиторов интегразы вич (варианты), набор и фармацевтическая композиция (варианты) | |
| WO2006091575A3 (en) | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts |